Companies › VivaTech International
1 active drug program in 3 registered trials: 3 Phase 2; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma ( Autologous adipose tissue-derived regenerative cells combined with platelet-derived growth | – | Phase 2 | Osteoarthritis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02844764 | Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma ( | Phase 2 | Osteoarthritis | Immunology | Aug 2026 |
| NCT02844738 | Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma ( | Phase 2 | Osteoarthritis | Immunology | Aug 2026 |
| NCT02844751 | Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma ( | Phase 2 | Osteoarthritis | Immunology | Aug 2026 |
No annotated target.
–
Aravax AltruBio Qu Biologics 4Moving Biotech Bluefin Biomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.